Mild To Moderate Alzheimer's Disease Dementia Therapeutics
1. Exelon patent expiration
Treatment: Treatment of alzheimer's dementia
EXELON IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6316023 | SANDOZ | TTS containing an antioxidant |
Jan, 2019
(7 years ago) | |
| US6335031 | SANDOZ | TTS containing an antioxidant |
Jan, 2019
(7 years ago) | |
| US4948807 | SANDOZ | Phenyl carbamates |
Aug, 2012
(13 years ago) | |
| US5602176 | SANDOZ | Phenyl carbamate |
Feb, 2014
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 31, 2015 |
| New Patient Population(NPP) | Jun 27, 2016 |
Drugs and Companies using RIVASTIGMINE ingredient
Market Authorisation Date: 06 July, 2007
Dosage: FILM, EXTENDED RELEASE
How can I launch a generic of EXELON before it's drug patent expiration?
More Information on Dosage
EXELON family patents
2. Exelon patent expiration
Treatment: Treatment of alzheimer's dementia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US4948807 | NOVARTIS | Phenyl carbamates |
Aug, 2012
(13 years ago) | |
| US5602176 | NOVARTIS | Phenyl carbamate |
Feb, 2014
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 31, 2015 |
| New Patient Population(NPP) | Jun 27, 2016 |
Drugs and Companies using RIVASTIGMINE TARTRATE ingredient
Market Authorisation Date: 21 April, 2000
Dosage: CAPSULE; SOLUTION
How can I launch a generic of EXELON before it's drug patent expiration?
More Information on Dosage
EXELON family patents